Date: March 24-27, 2002
Location: Montreux, Switzerland
The content presented here was prepared by independent authors under the editorial supervision of CancerConsultants and is not endorsed or sanctioned by the 28th Annual Meeting of the European Group for Blood and Marrow Transplantation: EBMT 2002.
Conference Summaries
What's New in Stem Cell Transplantation For AML: EBMT 2002
Allogeneic stem cell transplants have been an integral component of treatment of young patients since the 1970’s. In the early studies, approximately 10% of refractory patients could be cured with an allogeneic transplant from an HLA-matched sibling.
Stem Cell Transplants for ALL and Multiple Myeloma: An Update EBMT 2002
In children with ALL, allogeneic stem cell transplants are reserved for children with high-risk features and for those who have relapsed following treatment. For children who have failed chemotherapy, allogeneic transplants are more effective than continued chemotherapy.
The Impact of Gleevec: EBMT 2002
The 2002 meeting of the EBMT had 2,500 attendees from around the world. This meeting began 28 years ago with approximately 10 members who were called together by Dr. Bruno Speck from Basel, Switzerland to found the Society.
Treatment of Solid Tumor With Autologous or Allogeneic Stem Cell Transplants: EBMT 2002
The 2002 meeting of the EBMT had 2,500 attendees from around the world. This meeting began 28 years ago with approximately 10 members who were called together by Dr. Bruno Speck from Basel, Switzerland to found the Society.
Patient Home
2009 Coverage
